Skip to main content

Advertisement

Fig. 7 | Journal of Neuroinflammation

Fig. 7

From: Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease

Fig. 7

Lenalidomide inhibits NF-κB signaling and normalizes TNFα mRNA and protein levels in α-syn-treated microglial cells in vitro. a Microglial BV-2 cells were challenged with oligomeric recombinant human α-syn 5 μM for 1, 2, or 3 days, and protein extracts analyzed by immunoblot. Significant results of two independent samples per condition are shown. b Densitometric analysis of the levels of the NF-κB p65 immunoreactive band, expressed as the ratio between the nuclear and cytosolic fractions after the time course with α-syn. c qPCR analysis of the levels of TNFα mRNA after the time course with α-syn. d Densitometric analysis of the levels of the cytosolic TNFα immunoreactive band after the time course with α-syn. e BV-2 cells were challenged with oligomeric recombinant human α-syn 5 μM ± lenalidomide or thalidomide 250 μg/ml for 3 days, and protein extracts analyzed by immunoblot. Significant results of two independent samples per condition are shown. f Densitometric analysis of the levels of the NF-κB p65 immunoreactive band, expressed as the ratio between the nuclear and cytosolic fractions after 3 days of treatment. g qPCR analysis of the levels of TNFα mRNA after 3 days of treatment. h Densitometric analysis of the levels of the cytosolic TNFα immunoreactive band after 3 days of treatment. Error bars represent ± SEM. *, #p < 0.05

Back to article page